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Cdc25B and cdc25A phosphates are prominent stimulators of cell cycle progression and recent studies have also suggested
their oncogenic roles. To elucidate the role of these proteins in thyroid neoplasms, we immunohistochemically investigated
their expression, and neither protein was expressed in normal follicular cells. Cdc25B was frequently overexpressed in follicular
adenoma and minimally invasive follicular carcinoma, but the incidence was signiﬁcantly lower in widely invasive follicular
carcinoma. Furthermore, the cdc25B expression level signiﬁcantly decreased with the dedifferentiation of thyroid carcinoma.
Cdc25A overexpression was observed in high incidences in all types of thyroid neoplasms. These results suggest that cdc25B
and cdc25A play oncogenic roles in thyroid follicules and that cdc25B works predominantly in the early phase of the
progression of thyroid carcinoma, whereas cdc25A plays a fundamental role in the development of thyroid neoplasms.
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Thyroid carcinoma is one of the most common malignancies
originating from the endocrine organs. Two types of carcinoma
are known to occur from normal follicular cells, which are papil-
lary and follicular carcinomas. Follicular carcinoma is said to arise
from preexisting follicular adenoma, although this has not yet
been conﬁrmed. Precursor lesions of papillary carcinoma, on the
other hand, have not yet been identiﬁed (Faggin, 2000). It is well
known that the biological characteristics of these carcinomas are
generally mild and the prognosis is excellent if operated on
competently. However, anaplastic carcinoma, also known as undif-
ferentiated carcinoma, arises from papillary or follicular carcinoma
and is one of the most aggressive human carcinomas with a dire
prognosis. Although many kinds of therapeutic strategy have been
performed, most patients die within 6 months after diagnosis
(Aldinger et al, 1978). Furthermore, Sakamoto et al (1983)
demonstrated that papillary or follicular carcinoma with a solid,
trabecular or scirrhous growth pattern showed a worse clinical
outcome than pure papillary or follicular carcinoma. They
proposed a clinicopathological entity of poorly differentiated
carcinoma, and hypothesised that this type of carcinoma falls
between well differentiated carcinoma and undifferentiated carci-
noma, although it is still an open question whether showing
such growth patterns is truly due to the dedifferentiation of carci-
noma.
To evaluate the biological aggressiveness, one prominent factor
is the cell proliferating activity, which reﬂects the cell cycle progres-
sion. In the cell cycle, two checkpoints have been identiﬁed, which
are located in the G1-S phase and the G2-M phase. The complexes
of various cyclins and cyclin dependent kinases (CDKs) play a
crucial role in exceeding these checkpoints and CDKs should be
activated by phosphorylation in order to work as positive regula-
tors of the cell cycle (Sherr, 1994). Two kinds of phosphatase,
cdc25A and cdc25B are known to active CDKs, resulting in positive
regulation of the cell cycle progression (Galactinov and Beach,
1991). As cdc25A mRNA expression is elevated in the late G1
phase and the microinjection of a speciﬁc antibody against cdc25A
blocks G1-S transition, it is suggested that cdc25A activates the
CDKs, making a complex with the G1 cyclins (Jinno et al, 1994).
On the other hand, cdc25B plays a crucial role in G2-M transition,
of which the target should be cyclin B1/cdc2 complex (Lammer et
al, 1998). Furthermore, cdc25A and cdc25B can induce a malignant
transformation in rodent cells in cooperation with either Ha-
RASG12V or loss of RB1, indicating that they are potential onco-
genes (Galactinov et al, 1995).
The expression of cdc25A and cdc25B has been studied in some
human neoplasms and various results have been obtained (Kudo et
al, 1997; Wu et al, 1998; Broggini et al, 2000; Takemasa et al, 2000;
Nishioka et al, 2001; Sasaki et al, 2001). In thyroid carcinomas,
studying the modulation of cell proliferation is also important,
because the activity of cell proliferation strongly reﬂects the biolo-
gical aggressiveness of this carcinoma (Erickson et al, 1998). In this
study, therefore, we investigated the expression of cdc25A and
cdc25B in order to elucidate the role of these proteins as modula-
tors of the cell cycle progression of this carcinoma.
MATERIALS AND METHODS
Tissue specimens
Ten per cent formalin-ﬁxed, parafﬁn-embedded blocks were
prepared from the surgical specimens of 172 cases of thyroid
tumours. They consisted of 19 follicular adenomas, 26 minimally
invasive follicular carcinomas, 23 widely invasive follicular carcino-
mas, 72 cases of papillary carcinomas, and 32 cases of anaplastic
(undifferentiated) carcinomas. This project was approved by the
Ethics Committees of Kuma Hospital.
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Polyclonal antibodies against cdc25B (sc-326) and cdc25A (sc-97)
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). They were applied as primary antibodies at a concentration
of 1:200 and 1:400, respectively.
Immunohistochemistry
Tissue sections 4 mm thick were dewaxed and endogenous peroxi-
dase activity was blocked with 0.3% hydrogen peroxide in
methanol for 15 min. After rinsing in distilled water, the sections
were then immersed in 0.03 mol L
71 citrate buffer (pH 6.0) and
incubated at 958C for 40 min in a water bath for antigen retrieval.
After rinsing in phosphate-buffered saline pH 7.2 (PBS), 10%
bovine serum (Wako, Osaka, Japan) was applied for 20 min to
block nonspeciﬁc reactions. Sections were then incubated with
the primary antibody overnight at 48C. After rinsing in PBS, they
were treated with peroxidase-labelled anti-rabbit immunoglobulins
(Nichirei, Tokyo, Japan) for 30 min. The peroxidase reaction was
visualised by incubating the sections with 0.02% 3,3'-diaminoben-
zidine tetrahydrochloride in 0.05 M Tris buffer with 0.01%
hydrogen peroxide (Nichirei, Tokyo, Japan). The sections were
counterstained with haematoxylin. Sections for the negative control
were prepared using rabbit immunoglobulins instead of the
primary antibody.
Immunohistochemical evaluation
We regarded the cells as positive for these proteins when their
immunoreactivity was clearly observed in their nuclei or cyto-
plasms, or in both. We classiﬁed the cases into four categories
according to their positive cell rate as follows: (7), 510%, (+),
from 10 to 25%, (++), from 25 to 75%, (+++), 475%. We
regarded the cases classiﬁed as (++) or (+++) as overexpressing
these proteins.
Statistical analyses
We employed Fischer’s exact test for analyses of the relationship
between the expression of these proteins and their histological
types. P values less than 0.05 were regarded as statistically signiﬁ-
cant.
RESULTS
Expression of cdc25B
Cdc25B was not expressed in normal follicular cells or stromal
cells, including lymphocytes and epithelial cells of the blood vessels
(not shown), whereas it was predominantly expressed in the cyto-
plasms of tumour cells. In follicular tumours, cdc25B
overexpression was observed in 41 of the 68 cases (60.3%) (Figure
1A). In particular, follicular adenoma and minimally invasive folli-
cular carcinoma very frequently overexpressed cdc25B, 63.2% (12
of the 19 cases) and 73.1% (19 of the 26 cases), respectively. In
widely invasive follicular carcinoma, this phenomenon was seen
in only 43.5% (10 of the 23 cases) of the cases (Figure 1B), which
was signiﬁcantly lower (P=0.0456) than that in minimally invasive
carcinoma (Table 1).
In papillary carcinoma, 44 of the 72 cases (61.1%) overexpressed
cdc25B (Figure 1C), indicating that this phenomenon was observed
in 74 of the 121 cases (61.2%) of papillary or follicular carcinoma.
Among these cases, 43 had lesions showing a solid, trabecular or
scirrhous growth pattern, which was consistent with the criteria
of poorly differentiated carcinoma proposed by Sakamoto et al
(1983) (Figure 1C). Table 2 shows the relationship between cdc25B
overexpression and carcinoma differentiation. The incidence of
cdc25B overexpression in well differentiated carcinoma was
74.4% (58 of the 78 cases). It was signiﬁcantly higher than that
in poorly differentiated carcinoma (P50.0001), which was 37.2%
(16 of the 43 cases). In undifferentiated carcinoma, the incidence
was only 9.3% (three of the 32 cases) (Figure 1D), which was lower
than in poorly differentiated carcinoma (P=0.0072). Thus, the
reduced expression of cdc25B was signiﬁcantly linked to dedifferen-
tiation of thyroid carcinoma (P50.0001).
Expression of cdc25A
Cdc25A expression was not observed in normal follicular cells or
stromal cells (not shown). In thyroid neoplasms, its immunoreac-
tivity was localised in the nuclei or cytoplasms or in both. One
hundred and ﬁve cases of 153 thyroid carcinomas (68.7%) (Figure
2A,B) and six cases of 19 adenomas (31.6%) overexpressed cdc25A
(Figure 2C). Among them, cdc25A was localised predominantly in
the cell nuclei in 29 carcinomas (27.6%) (Figure 2B) and three
adenomas (50%), in the cytoplasms in 66 carcinomas (62.9%)
(Figure 2A) and two adenomas (33.3%), and in the remaining
10 carcinomas (9.5%) and one adenoma (16.7%) (Figure 2C), it
was expressed both in the nuclei and cytoplasms in similar inci-
dences. We investigated the relationship between the cell
localisation of cdc25A and histological types, but no statistically
signiﬁcant relationships were established (not shown).
We investigated the relationship between cdc25A expression and
clinicopathological features, as shown in Tables 3 and 4, although
we could not establish any signiﬁcance. Furthermore, no relation-
ships were determined between the expression of cdc25A and
cdc25B in any histological types (data not shown).
DISCUSSION
In this study, we demonstrated that (1) cdc25B and cdc25A were
not overexpressed in normal thyroid tissue, (2) cdc25B was
frequently overexpressed in follicular adenoma and minimally inva-
sive follicular carcinoma, but the incidence signiﬁcantly decreased
in widely invasive follicular carcinoma, (3) the incidence of cdc25B
overexpression signiﬁcantly decreased with the dedifferentiation of
carcinoma, and (4) cdc25A was frequently overexpressed in thyroid
neoplasms regardless of their histological types.
A difference in cell localisation between these two phosphatases
has been reported. Previous in vitro and clinical studies indicated
the cytoplasmic accumulation of cdc25B, which is in agreement
with our ﬁndings (Gabrielli et al, 1996; Gasparotte et al, 1997;
Kudo et al, 1997; Broggini et al, 2000; Takemasa et al, 2000;
Nishioka et al, 2001). On the other hand, Dixon et al (1998)
showed an elevated expression of cdc25A in nuclear fractions of
colon carcinoma, which was conﬁrmed by immunohistochemical
study (Takemasa et al, 2000). However, in oesophageal carcinoma,
similar to our results, cdc25A was accumulated both in cyto-
plasms and nuclei (Nishioka et al, 2001), and in ovarian
carcinoma, its immunoreactivity was seen mainly in cytoplasms
(Broggini et al, 2000), indicating that the localisation of this phos-
phatase depends on the origin of the carcinoma.
What is most interesting in this study is the inverse relationship
between cdc25B overexpression and the biological aggressiveness of
the thyroid tumour, because such an expression status has not been
observed in other positive regulators of cell cycle. Wang et al
(2000) demonstrated that cyclin D1 was more frequently overex-
pressed in more aggressive thyroid carcinomas such as anaplastic
carcinoma, tall cell variant, and insular carcinoma. On the other
hand, Goto et al (2001) showed that cyclin D1 was frequently over-
expressed in thyroid carcinoma but rarely in benign adenoma.
Furthermore, our recent study showed that cyclin A expression
level increased with dedifferentiation of thyroid carcinoma and
cyclin B1 overexpression was found exclusively in undifferentiated
carcinoma (manuscript submitted). It is thus suggested that the
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British Journal of Cancer (2002) 86(12), 1909–1913 ã 2002 Cancer Research UKreduced expression of cdc25B in dedifferentiated carcinoma is
unique compared to other cell cycle regulatory proteins.
The expression status of cdc25B in thyroid tumours differs from
that in other carcinomas. Previous studies have demonstrated that
cdc25B overexpression reﬂects a worse clinical outcome in patients
with colorectal (Takemasa et al, 2000), ovarian (Broggini et al,
2000), and non-small-cell lung carcinomas (Sasaki et al, 2001).
In gastric carcinoma, cdc25B expression was associated with
advanced stage and deep invasion (Galactinov et al, 1995).
However, the physiological roles of cdc25B in carcinomas do not
appear to be simple. Takemasa et al (2000) demonstrated that,
although cdc25B overexpression can be regarded as an independent
prognostic factor in colorectal carcinoma, it is not related to the
cell proliferating activity evaluated by the Ki-67 labelling index.
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Figure 1 Immunostaining of cdc25B. (A) cdc25B overexpression in minimally invasive follicular carcinoma (+++). (B) cdc25B overexpression in widely
invasive follicular carcinoma with solid growth pattern (++). (C) cdc25 overexpression in papillary carcinoma (+++). (D) cdc25 was negative in undiffer-
entiated carcinoma (7).
Table 1 Relationship between cdc25B overexpression and histological
type of follicular tumour
Cdc25B overexpression + 7 Total
Follicular carcinoma
*Widely invasive 10 13 23
*Minimally invasive 19 7 26
Follicular adenoma 12 7 19
Total 41 27 68
*P=0.0456 (Fisher’s exact test).
Table 2 Relationship between cdc25B overexpression and the differen-
tiation of thyroid carcinoma
Cdc25B overexpression + 7 Total
Undifferentiated carcinoma 3 29 32
Papillary or follicular carcinoma 74 47 121
With solid, trabecular or scirrhous growth pattern 16 27 43
(poorly differentiated)
Pure papillary or follicular carcinoma 58 20 78
(well differentiated)
Total 77 76 153
P50.0001 (undifferentiated carcinoma vs poorly differentiated carcinoma vs well
differentiated carcinoma). P50.0001 (well differentiated carcinoma vs poorly differ-
entiated carcinoma). P=0.0072 (undifferentiated carcinoma vs poorly differentiated
carcinoma).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1909–1913These ﬁndings are strange, because cdc25B fundamentally acts as a
positive regulator of cell cycle progression. They thus hypothesised
that cdc25B itself displays oncogenic properties by enhancing the
malignant nature of this carcinoma. Also, in thyroid carcinoma,
the clinical signiﬁcance of cdc25B overexpression is very compli-
cated. Previous studies have demonstrated that, in thyroid
neoplasms, cell proliferating activity is usually low, except for its
drastic elevation in undifferentiated carcinoma (Erickson et al,
1998). This study showed the frequent overexpression of cdc25B
in benign adenoma and carcinomas with low aggressive phenotypes
and its decreased expression in those of very aggressive types, such
as undifferentiated carcinoma and widely invasive follicular carci-
noma, indicating that cdc25B expression is even inversely linked
to the cell proliferating activity of thyroid neoplasms. It is thus
suggested that cdc25B plays a crucial role in the progression of
thyroid carcinoma in the early stage, as well as in the tumorigenesis
of follicular cells of the thyroid, rather than merely in tumour cell
proliferation. This protein does not seem to be necessary for the
development of thyroid carcinoma after it achieves high proliferat-
ing activity, including dedifferentiation.
The clinical signiﬁcance of cdc25A in carcinoma also seems to
vary, because different results have been reported for carcinomas
of different origin (Broggini et al, 2000; Takemasa et al, 2000;
Nishioka et al, 2001). In oesophageal and ovarian carcinomas, its
overexpression signiﬁcantly predicts a poor prognosis whereas no
such relation could be established in colorectal carcinoma. Accord-
ing to our ﬁndings, cdc25A was frequently overexpressed in all
types of thyroid neoplasms including benign adenoma arising from
follicular cells. Unlike cdc25B, the incidence of cdc25A overexpres-
sion did not decrease in carcinomas with aggressive phenotypes. It
is therefore suggested that this phosphatase plays a fundamental
role in the oncogenesis of thyroid follicles and also in the develop-
ment of thyroid neoplasms, regardless of histological type. Previous
studies have shown that the overexpression of G1 cyclins could be
observed in thyroid neoplasms of various types in similar inci-
dences (Wang et al, 2000; Goto et al, 2001). Thus, we can
hypothesise that cdc25A may be linked to the activation of cdks,
making complexes with cyclins, although it is unlikely that both
cdc25A and cdk-G1 cyclin complex are directly related to the cell
proliferating activity of thyroid neoplasms.
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Figure 2 Immunostaining of cdc25A. (A) cdc25A overexpression in cy-
toplasms of papillary carcinoma (+++). (B) cdc25A overexpression in cell
nuclei of undifferentiated carcinoma (+++). (C) cdc25A overexpression in
cytoplasms and cell nuclei of follicular adenoma (+++). Scale bars: 150 mm.
Table 3 Relationship between cdc25A overexpression and histological
type of follicular tumour
Cdc25A overexpression + 7 Total
Follicular carcinoma
Widely invasive 13 10 23
Minimally invasive 13 13 26
Follicular adenoma 6 13 19
Total 42 26 68
Not signiﬁcant.
Table 4 Relationship between cdc25A overexpression and the
differentiation of thyroid carcinoma
Cdc25A overexpression + 7 Total
Undifferentiated carcinoma 17 15 32
Papillary or follicular carcinoma 88 33 121
With solid, trabecular or scirrhous growth pattern 34 9 43
(poorly differentiated)
Pure papillary or follicular carcinoma 54 24 78
(well differentiated)
Total 105 48 153
Not signiﬁcant.
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British Journal of Cancer (2002) 86(12), 1909–1913 ã 2002 Cancer Research UKThe signiﬁcant reduction of cdc25B expression in dedifferen-
tiated thyroid carcinoma has prompted researchers to investigate
its prognostic value. Of the 32 undifferentiated carcinomas in
our series, only 17 cases could undergo curative surgery. Among
them, one case which overexpressed cdc25B has survived for 6
months after surgery, whereas the three long term survival cases,
82, 56, and 44 months, did not overexpress cdc25B. We therefore
failed to establish the prognostic value of cdc25B expression, but
further studies with a larger number of cases undergoing curative
surgery are necessary to draw a deﬁnitive conclusion about this
point.
In summary, this study demonstrated that cdc25B and cdc25A
may play an oncogenic role in thyroid neoplasms but may not
be directly linked to the cell proliferation of thyroid tumours.
Further studies are necessary to more clearly elucidate the signiﬁ-
cance of these proteins in thyroid neoplasms.
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